LUNG CANCER PRENEOPLASIA
- 1 February 2006
- journal article
- review article
- Published by Annual Reviews in Annual Review Of Pathology-Mechanisms Of Disease
- Vol. 1 (1) , 331-348
- https://doi.org/10.1146/annurev.pathol.1.110304.100103
Abstract
From histological and biological perspectives, lung cancer is a complex neoplasm. Although the sequential preneoplastic changes have been defined for centrally arising squamous carcinomas of the lung, they have been poorly documented for the other major forms of lung cancers, including small cell lung carcinoma and adenocarcinomas. There are three main morphologic forms of preneoplastic lesions recognized in the lung: squamous dysplasias, atypical adenomatous hyperplasia, and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. However, these lesions account for the development of only a subset of lung cancers. Several studies have provided information regarding the molecular characterization of lung preneoplastic changes, especially for squamous cell carcinoma. These molecular changes have been detected in the histologically normal and abnormal respiratory epithelium of smokers. Two different molecular pathways have been detected in lung adenocarcinoma pathogenesis: smoking-associated activation of RAS signaling, and nonsmoking-associated activation of EGFR signaling; the latter is detected in histologically normal respiratory epithelium.Keywords
This publication has 69 references indexed in Scilit:
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor in Non–Small Cell Lung CancerClinical Cancer Research, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Survivin Expression in Atypical Adenomatous Hyperplasia of the LungAmerican Journal of Clinical Pathology, 2003
- Gene-expression profiles predict survival of patients with lung adenocarcinomaNature Medicine, 2002
- Loss of Heterozygosity on Chromosomes 9q and 16p in Atypical Adenomatous Hyperplasia Concomitant with Adenocarcinoma of the LungThe American Journal of Pathology, 2001
- Monoclonality of Atypical Adenomatous Hyperplasia of the LungThe American Journal of Pathology, 1999